

The future of pharmaceutical pricing, transparency and access to medicines

15th September 2016

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt, please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Jo Churchill MP, Vice Chair, All-Party Parliamentary Group on Cancer (<i>transcript</i>)	6
<u>The new policy landscape for life sciences and the Accelerated Access Review</u>	
Nicole Mather, Director, Office for Life Sciences and Lead, Accelerated Access Review (<i>transcript</i>)	7
Questions and comments from the floor (<i>transcript</i>)	12
<u>Challenges for regulation, adaptive pathways and challenges for the European Medicines Agency</u>	
Dr Ian Hudson, Chief Executive, MHRA and Member (UK), Management Board, European Medicines Agency (<i>transcript</i>)	14
Questions and comments from the floor (<i>transcript</i>)	18
<u>Key issues in access to medicines: drug development, pricing models and demand</u>	
Professor Gary Ford, Chief Executive, Oxford Academic Health Science Network (<i>transcript</i>)	22
Professor Karl Claxton, Professor of Economics, University of York and former Member, NICE Appraisal Committee (<i>transcript</i>)	24
Angela Culhane, Chief Executive Officer, Prostate Cancer UK (<i>transcript</i>)	26
Adam Kundzewicz, Senior Global Payer Strategy Manager and Head of Pricing - UK, Boehringer Ingelheim (<i>transcript</i>)	28
Questions and comments from the floor (<i>transcript</i>)	30
<u>Session Chair's closing remarks</u>	
Jo Churchill MP, Vice Chair, All-Party Parliamentary Group on Cancer (<i>transcript</i>)	37
<u>Session Chair's opening remarks</u>	
Daniel Zeichner MP, Vice Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	38
<u>Tackling key issues for the pharmaceutical industry: financial risk, compliance and supply chain effectiveness</u>	
Dr Myrto Lee, Director, Strategy& (<i>transcript</i>)	39
Dr Rick Greville, Director of Distribution and Supply, ABPI (<i>transcript</i>)	42
Questions and comments from the floor (<i>transcript</i>)	44
<u>Promoting transparency and challenges for managing conflicts of interest between healthcare and industry</u>	
Dr Waqar Shah, Clinical Expert in Eye Health, Royal College of General Practitioners and Chair, Macular Degeneration Committee, NICE (<i>transcript</i>)	49
Pat Treacy, Partner, Bristows (<i>transcript</i>)	52
Sophie Peresson, Director, Pharmaceuticals and Healthcare Programme, Transparency International UK (<i>transcript</i>)	54
Questions and comments from the floor (<i>transcript</i>)	56
<u>Next steps for the NICE appraisal process: cost effectiveness and market access</u>	
Dr Nick Crabb, Programme Director, Scientific Affairs, NICE (<i>transcript</i>)	59
Questions and comments from the floor (<i>transcript</i>)	62
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Daniel Zeichner MP, Vice Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	65
Amy Cutter, Producer, Westminster Health Forum (<i>transcript</i>)	66
<u>Comments</u>	67
Angela Culhane, Chief Executive Officer, Prostate Cancer UK	
<u>List of Delegates Registered for Seminar</u>	69
<u>Contributor Biographies</u>	75
<u>About the Core Sponsors of the Westminster Health Forum</u>	78

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: The future of pharmaceutical pricing, transparency and access to medicines held on 15th September 2016. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796

F: 01344 420121

publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder
Chris Whitehouse